====== Jaahnavi Dave ======

{{ ::jaahnavi_dave_.jpeg?200|}}

**Jaahnavi Dave** is a PhD student based in [[canada:ontario:Ottawa]], [[canada:Ontario]]. She works in the [[cancer immunotherapy]] program at the [[Ottawa Hospital Research Institute]] in the lab of [[John Bell]].((//Bell Lab - Lab Members.// Ottawa Hospital Research Institute. Retrieved March 19, 2023, from https://web.archive.org/web/20230319174921/https://www.ohri.ca/profile/jbell/lab-members))

===== History =====

==== Education ====

In January-May 2018, Dave worked as a research intern at the [[Goodman Cancer Research Centre]] at [[McGill University]].

As an undergraduate student at [[McGill University]], Dave participated in [[BioCanRx]]'s 2018 Summer Studentship Program. She worked in the laboratory of [[Denis Claude Roy]] at the [[Université de Montréal]] and [[Hôpital Maisonneuve-Rosemont]].((//Introducing the winners of BioCanRx’s 2018 Summer Studentships.// (2018, April 26). BioCanRx. https://web.archive.org/web/20230316080713/https://biocanrx.com/introducing-winners-biocanrx-2018-summer-studentships)) She conducted research on targeted cell therapy funded by BioCanRx.((//BioCanRx Summer Students Tell All.// (2018, September 21). BioCanRx. https://web.archive.org/web/20220429044210/https://biocanrx.com/biocanrx-summer-students-tell))

Dave won the first place prize for best oral presentation at the 2019 [[Ontario-Quebec Undergraduate Immunology Conference]].((//Jaahnavi Dave - LinkedIn Profile.// (2023, March 19). Internet Archive; LinkedIn. https://archive.org/details/jaahnavi-dave-linkedin-profile)) Starting in May 2019, she participated in a summer internship with the [[National Research Council Canada]] in the Human Health Therapeutics department.((Shared Services Canada. (2020, October 10). //Person Information - Jaahnavi Dave - Student.// Government of Canada. https://web.archive.org/web/20221004005410/https://geds-sage.gc.ca//en/GEDS?pgid=015&dn=Q049REFWRVwyQyBKQUFITkFWSSxPVT1ISFQtVFNILE9VPUxTLVNWLE9VPU5SQy1DTlJDLE89R0MsQz1DQQ==))
==== COVID-19 ====

In May 2021, Dave co-signed an open letter to Prime Minister [[Justin Trudeau]] calling on him to issue a temporary waiver on [[Canada]]'s intellectual property rights on [[COVID-19 vaccines]] and to provide them to the [[World Health Organization]]'s [[COVID-19 Technology Access Pool]] (C-TAP).((//Dear Prime Minister: “The time to show leadership on global vaccination efforts is now.”// (2021, May 10). Maclean’s. http://archive.today/2023.03.19-174329/https://macleans.ca/opinion/dear-prime-minister-the-time-to-show-leadership-on-global-vaccination-efforts-is-now/)) During this same period, Dave was communicating by e-mail as part of the [[Public Health Agency of Canada]] (PHAC)'s COVID-19 Therapeutics Team.((Cortés-Kaplan, S. (2021). //Release Package - PHAC- A-2021-000129 - 2022-04-12.// In Internet Archive (p. 6). Public Health Agency of Canada. https://ia801609.us.archive.org/34/items/release-package-phac-a-2021-000129-2022-04-12/ReleasePackage%20-%20PHAC-%20A-2021-000129%20-%202022-04-12_text.pdf))

===== Activities =====

==== Research ====

Dave has published research funded by a [[Fonds de Recherche de Québec - Santé]] Schan Ontario Graduate Scholarship.((Surendran, A., Jamalkhah, M., Poutou, J., Birtch, R., Lawson, C., Dave, J., Crupi, M. J. F., Mayer, J., Taylor, V., Petryk, J., de Souza, C. T., Moodie, N., Billingsley, J. L., Austin, B., Cormack, N., Blamey, N., Rezaei, R., McCloskey, C. W., Fekete, E. E. F., & Birdi, H. K. (2023). //Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy via lipid modulation of the tumor microenvironment.// Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1099459))

She also published a paper funded by [[Mitacs]], [[Ottawa Hospital Foundation]], the [[Thistledown Foundation]], the [[Terry Fox Research Institute]], and the [[Canadian Cancer Society]] on [[TOH-Vac1]], a [[COVID-19 vaccines|COVID-19 vaccine]] candidate based on the original [[smallpox vaccine]].((Boulton, S., Poutou, J., Martin, N. T., Azad, T., Singaravelu, R., Crupi, M. J. F., Jamieson, T., He, X., Marius, R., Petryk, J., Tanese de Souza, C., Austin, B., Taha, Z., Whelan, J., Khan, S. T., Pelin, A., Rezaei, R., Surendran, A., Tucker, S., & Fekete, E. E. F. (2022). //Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection.// Molecular Therapy, 30(5), 1885–1896. https://doi.org/10.1016/j.ymthe.2021.10.008))

===== External links =====

  * [[https://www.researchgate.net/profile/Jaahnavi_Dave|ResearchGate]]